BC Extra | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy  Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive rights to develop and commercialize tapinarof in Japan for dermatology indications including psoriasis and atopic dermatitis. The...
BC Innovations | Dec 19, 2019
Distillery Therapeutics

Gut microbe metabolites as treatments for iron overload

DISEASE CATEGORY: Hematology INDICATION: Iron overload The microbial metabolites diaminopropane and reuterin could treat iron overload by inhibiting HIF2A, which promotes iron absorption from the gut. Microbes in the gut compete with the host to...
BC Extra | Oct 8, 2019
Tools & Techniques

Nobel Prize for cell response to oxygen, a two-sided therapeutic target

Cellular responses to oxygen levels, the focus of this year's Nobel Prize in Physiology or Medicine, are the targets of both inhibiting and activating therapies in clinical development for multiple diseases. William Kaelin, Peter Ratcliffe...
BC Week In Review | Jul 12, 2019
Company News

First domestic company gets a first-in-class approval in China

China's National Medical Products Administration (NMPA) approved in May an NDA from Beijing Wenfeng Tianji Pharmaceuticals Co. Ltd. (Beijing, China) for tapinarof (DMVT-505, WBI-1001, benvitimod) to treat mild to moderate stable psoriasis vulgaris. The product...
BC Extra | May 25, 2019
Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
BC Innovations | Mar 25, 2019
Distillery Techniques

AHR levels in tumors predict response to Keytruda and other anti-PD-1 therapies in NSCLC

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Tissue markers Tumor levels of AHR could help predict response to Keytruda pembrolizumab and other PD-1 inhibitors in NSCLC. In 37 patients treated with Keytruda, high tumor levels of AHR protein...
BC Week In Review | Jan 25, 2019
Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced on Jan. 18 by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes...
BC Extra | Jan 19, 2019
Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes...
BioCentury | Dec 14, 2018
Emerging Company Profile

ExCellThera’s safer allogeneic transplants

ExCellThera Inc. is expanding cord blood into allogeneic stem cell transplants for cancer that have lower treatment-related mortality rates and GvHD incidence than competing technologies. Hematopoietic stem cell transplants (HSCTs) of unexpanded cord blood have...
Items per page:
1 - 10 of 59